Osteoimmunology and the effects of the immune system on bone

Nature Reviews Rheumatology

Volumn 5, Issue 12, 2009, Pages 667-676

  Takayanagi, Hiroshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; INTERLEUKIN 17; MEMBRANE RECEPTOR; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

BONE DESTRUCTION; BONE METABOLISM; CALCIUM SIGNALING; CELL DIFFERENTIATION; CELL INTERACTION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG TARGETING; HELPER CELL; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INDUCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; T LYMPHOCYTE; TH17 CELL;

ARTHRITIS, RHEUMATOID; BONE AND BONES; HUMANS; OSTEOCLASTS; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 75049085147     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.217     Document Type: Review

References (87)

1. Okada, Y., Nagase, H. & Harris, E. D., Jr. Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. J. Rheumatol. 14 (Spec. No), 41-42 (1987).
2. Bromley, M. & Woolley, D. E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 27, 968-975 (1984).
3. Gravallese, E. M. et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152, 943-951 (1998).
4. Takayanagi, H. et al. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem. Biophys. Res. Commun. 240, 279-286 (1997).
5. Takayanagi, H. et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43, 259-269 (2000).
6. Takahashi, N. et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600-2602 (1988).
7. Takayanagi, H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292-304 (2007).
8. Suda, T. et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357 (1999).
9. Theill, L. E., Boyle, W. J. & Penninger, J. M. rANK-L and rANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20, 795-823 (2002).
10. Anderson, D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997).
11. Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TrANCe/rANKL. Proc. Natl Acad. Sci. USA 95, 3597-3602 (1998).
12. Wong, B. R. et al. TrANCe is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-25194 (1997).
13. Kong, Y. Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309 (1999).
14. Gravallese, E. M. et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43, 250-258 (2000).
15. Pettit, A. R. et al. TrANCe/rANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159, 1689-1699 (2001).
16. redlich, K. et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110, 1419-1427 (2002).
17. McClung, M. r. et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821-831 (2006).
18. Bone, H. G. et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93, 2149-2157 (2008).
19. Cohen, S. B. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58, 1299-1309 (2008).
20. Kearns, A. E., Khosla, S. & Kostenuik, P. J. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 29, 155-192 (2008).
21. Horwood, N. J. et al. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265, 144-150 (1999).
22. Takayanagi, H. et al. T cell-mediated regulation of osteoclastogenesis by signalling cross-talk between rANKL and IFN-γ. Nature 408, 600-605 (2000).
23. Teng, Y. T. et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J. Clin. Invest. 106, r59-r67 (2000).
24. Firestein, G. S. & Zvaifler, N. J. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 33, 768-773 (1990).
25. Kotake, S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 109, 1345-1352 (1999).
26. Kastelein, R. A., Hunter, C. A. & Cua, D. J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25, 221-242 (2007).
27. Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673-2682 (2006).
28. Lubberts, E. et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J. Clin. Invest. 105, 1697-1710 (2000).
29. Finnegan, A. et al. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Statdependent mechanisms. J. Immunol. 169, 3345-3352 (2002).
30. Irmler, I. M., Gajda, M. & Brauer, R. Exacerbation of antigen-induced arthritis in IFN-γ-deficient mice as a result of unrestricted IL-17 response. J. Immunol. 179, 6228-6236 (2007).
31. Matthys, P. et al. Anti-IL-12 antibody prevents the development and progression of collageninduced arthritis in IFN-γ receptor-deficient mice. Eur. J. Immunol. 28, 2143-2151 (1998).
32. Mizoguchi, T. et al. Identification of cell cyclearrested quiescent osteoclast precursors in vivo. J. Cell. Biol. 184, 541-554 (2009).
33. Kwak, H. B. et al. Reciprocal cross-talk between rANKL and interferon-γ-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum. 58, 1332-1342 (2008).
34. Kim, N., Odgren, P. R., Kim, D. K., Marks, S. C., Jr & Choi, Y. Diverse roles of the tumor necrosis factor family member TrANCe in skeletal physiology revealed by TrANCe deficiency and partial rescue by a lymphocyte-expressed TrANCe transgene. Proc. Natl Acad. Sci. USA 97, 10905-10910 (2000).
35. Sobacchi, C. et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding rANKL. Nat. Genet. 39, 960-962 (2007).
36. + T cells. Arthritis Res. Ther. 7, r291-r301 (2005).
37. Zaiss, M. M. et al. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum. 56, 4104-4112 (2007).
38. Wakkach, A. et al. Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood 112, 5074-5083 (2008).
39. Yamashita, T. et al. NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (rANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J. Biol. Chem. 282, 18245-18253 (2007).
40. Wan, Y., Chong, L. W. & Evans, R. M. PPAr-γ regulates osteoclastogenesis in mice. Nat. Med. 13, 1496-1503 (2007).
41. Sato, K. et al. Regulation of osteoclast differentiation and function by the CaMK-CreB pathway. Nat. Med. 12, 1410-1416 (2006).
42. Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate rANKL signaling for terminal differentiation of osteoclasts. Dev. Cell 3, 889-901 (2002).
43. Asagiri M. et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202, 1261-1269 (2005).
44. winslow, M. M. et al. Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev. Cell 10, 771-782 (2006).
45. Aliprantis, A. O. et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J. Clin. Invest. 118, 3775-3789 (2008).
46. Koga, T. et al. Costimulatory signals mediated by the ITAM motif cooperate with rANKL for bone homeostasis. Nature 428, 758-763 (2004).
47. Mocsai, A. et al. The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (Fcrγ) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl Acad. Sci. USA 101, 6158-6163 (2004).
48. Takegahara, N. et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat. Cell Biol. 8, 615-622 (2006).
49. Mori, Y. et al. Inhibitory immunoglobulin-like receptors LILrB and PIr-B negatively regulate osteoclast development. J. Immunol. 181, 4742-4751 (2008).
50. Shinohara, M. et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking rANK and ITAM signals. Cell 132, 794-806 (2008).
51. i oscillation regulation. Genes Dev. 21, 1803-1816 (2007).
52. Masuyama, R. et al. TrPv4-mediated calcium influx regulates terminal differentiation of osteoclasts. Cell Metab. 8, 257-265 (2008).
53. 2+ oscillation-independent NFATc1 activation during osteoclastogenesis. Proc. Natl Acad. Sci. USA 105, 8643-8648 (2008).
54. 2+ oscillation. EMBO J. 22, 3825-3832 (2003).
55. Smolen, J. S. et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 52, 1020-1030 (2005).
56. Ochi, S. et al. Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc. Natl Acad. Sci. USA 104, 11394-11399 (2007).
57. hi osteoclast precursors but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J. Bone Miner. Res. 19, 207-213 (2004).
58. Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156-163 (2007).
59. Feldmann, M., Brennan, F. M. & Maini, R. N. Rheumatoid arthritis. Cell 85, 307-310 (1996).
60. Iwakura, Y. & Ishigame, H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116, 1218-1222 (2006).
61. Mihara, M., Ohsugi, Y. & Kishimoto, T. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody. Biofactors 35, 47-51 (2009).
62. Urushibara, M. et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-κB ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum. 50, 794-804 (2004).
63. Kitahara, K. & Kawai, S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr. Opin. Rheumatol. 19, 238-245 (2007).
64. Suematsu, A. et al. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod. Rheumatol. 17, 17-23 (2007).
65. Lee, C. K. et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand. Arthritis Rheum. 50, 3831-3843 (2004).
66. Kollet, O., Dar, A. & Lapidot, T. The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu. Rev. Immunol. 25, 51-69 (2007).
67. Nagasawa, T. Microenvironmental niches in the bone marrow required for B-cell development. Nat. Rev. Immunol. 6, 107-116 (2006).
68. Kollet, O. et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 12, 657-664 (2006).
69. Ishii, M. et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458, 524-528 (2009).
70. Asagiri, M. et al. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 319, 624-627 (2008).
71. Ewald, S. E. et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456, 658-662 (2008).
72. Park, B. et al. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat. Immunol. 9, 1407-1414 (2008).
73. Hummel, K. M. et al. Cysteine proteinase cathepsin K mrNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J. Rheumatol. 25, 1887-1894 (1998).
74. Hou, W. S. et al. Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am. J. Pathol. 159, 2167-2177 (2001).
75. Walsh, M. C. et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 24, 33-63 (2006).
76. Bachmann, M. F. et al. TrANCe, a tumor necrosis factor family member critical for CD40 ligandindependent T helper cell activation. J. Exp. Med. 189, 1025-1031 (1999).
77. Ashcroft, A. J. et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19, 849-861 (2003).
78. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
79. Dougall, w. C. et al. rANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424 (1999).
80. Li, J. et al. rANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl Acad. Sci. USA 97, 1566-1571 (2000).
81. + Treg cells: highly potent regulators of diabetes that require TrANCe-rANK signals. Immunity 16, 183-191 (2002).
82. Loser, K. et al. Epidermal rANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat. Med. 12, 1372-1379 (2006).
83. Akiyama, T. et al. The tumor necrosis factor family receptors rANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 29, 423-437 (2008).
84. Hikosaka, Y. et al. The cytokine rANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 29, 438-450 (2008).
85. Whyte, M. P. Paget's disease of bone and genetic disorders of rANKL/OPG/rANK/NF-κB signaling. Ann. NY Acad. Sci. 1068, 143-164 (2006).
86. Hocking, L. J. et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum. Mol. Genet. 11, 2735-2739 (2002).
87. Arron, J. R. et al. NFAT dysregulation by increased dosage of DSCr1 and DYrK1A on chromosome 21. Nature 441, 595-600 (2006)